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Summary
We have generated immunodeficient scid-/scid- (SCID)-transgenic mice expressing the genes
for human interleukin 3, granulocyte/macrophage-colony stimulating factor, and stem cell fac-
tor. We have compared engraftment and differentiation of human hematopoietic cells in trans-
genic SCID mice with two strains of nontransgenic SCID mice. Human bone marrow cells
carrying the CD34 antigen or human umbilical cord blood were injected into sublethally irra-
diated recipients. Human DNA was detected by polymerase chain reaction in peripheral blood
and bone marrow of 14 of 28 transgenic SCID mice after transplantation, but in only 2 of 15
nontransgenic SCID littermates at a 10-fold lower level. Bone marrow cultures 8 wk after
transplantation of cord blood gave rise to human burst-forming unit erythroid, colony-forming
unit granulocyte/macrophage, or granulocyte/erythroid/macrophage/megakaryocyte colonies.
Engraftment was observed for up to 6 mo in transgenic SCID mice, twice as long as nontrans-
genic littermates or previous studies in which transplanted SCID mice were given daily injec-
tions ofgrowth factors. We conclude that the level and duration ofengraftment ofhuman cells
in SCID mice can be improved by expression of human cytokine transgenes and that trans-
genic SCID mice are an efficient model system for the study ofhuman hematopoiesis.
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Most of our knowledge about human hematopoiesis
has been derived from studies ofhuman cells in vitro
(for reviews see references 1-4) . These studies generated
information about the phenotype ofprimitive and commit-
ted progenitors, their lineage relationships, and their differ-
entiation programs, and led to the identification of a broad
spectrum of growth factors and biomolecules that modulate
and regulate human hematopoiesis (5). In the murine sys-
tem, multiple in vivo assays have been established that de-
fine the properties of the most primitive hematopoietic
cells (6) . Because the study of human hematopoiesis would
be enhanced by an in vivo model, multiple strategies have
been pursued to develop an animal recipient for human he-
matopoietic cells. In sheep and monkey models, intrauterine
injection of human fetal liver cells has reproducibly resulted
in long-term engraftment, proliferation, and differentiation
of human hematopoietic cells (7, 8). Genetically immuno-
deficient mouse strains provide a small animal model for
the propagation of human hematopoietic cells. Mice ho-
mozygous for the SCID mutation (scid -/scid-; abbreviated
SCID) are widely used for xenogeneic transplantation of
hematopoietic cells (9). SCID mice are severely deficient in
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functional B and T lymphocytes because of impaired re-
combination ofimmunoglobulin and T cell receptor genes,
which causes an early arrest in the development of B and T
lineage-committed cells; other hematopoietic cells appear
normal (9, 10) . All cell types are highly sensitive to ionizing
radiation, since the scid mutation also affects the DNA repair
mechanism (11, 12). Mutations in the DNA-dependent ki-
nase gene have been proposed as the underlying defect (11) .
To provide support for the optimal growth and differen-
tiation ofhuman hematopoietic cells transplanted into SCID
mice, several strategies have been pursued. In the SCID-hu
model, human fetal liver cells are cotransplanted with hu-
man fetal thymus into SCID mice (13-15). It was proposed
that the human fetal thymus graft provided a human mi-
croenvironment and cytokines. Human cells differentiated
into multiple lineages, including T lymphocytes, and could
be monitored for up to several months in the majority of
hosts. In another model, transplantation of human bone
marrow, fetal liver, or umbilical cord blood cells was com-
bined with the injection of the recombinant cytokines hu-
man stem cell factor (hSCF;' steel factor, c-kit ligand, mast
cell growth factor), PIXY 321, a fusion protein of human
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CSF) (16, 17) . These cytokines were selected because SCF,
GM-CSF, and IL-3 are known to be species specific (18,
19) and because hSCF, hGM-CSF, and hIL-3 together can
promote growth and differentiation of bone marrow pro-
genitor cells in vitro (20) . Repetitive injection of high
doses of these cytokines supported engraftment of human
bone marrow and umbilical cord blood cells in a large por-
tion of transplanted animals routinely for 8 wk, and occa-
sionally up to 14 wk (17, 21) ; cord blood also engrafted
SCID mice without exogenous cytokines (21) .
In spite of these achievements, the strategies described
have drawbacks . The availability of fetal tissue is often re-
stricted, and transplant surgery risks the health of the infec-
tion-prone recipient animals . Finally, there is a wide variabil-
ity in the engraftment ofhuman cells into different strains
ofSCID mice . As an alternative to earlier models, we have
generated a transgenic SCID mouse that carries the genes
for hIL-3, hGM-CSF, and hSCF . We hypothesized that
the transgenes would support the long-term engraftment of
human hematopoietic cells in these mice by providing hu-
man-specific cytokines . Our data indicate that SCID mice
transgenic for hIL-3, hGM-CSF, and hSCF can support
long-term engraftment of human hematopoietic cells and
can be considered a suitable in vivo model for human he-
matopoiesis .
Materials and Methods
Generation of Transgenic SCID Mice .
￿
BALB/cBy, BALB/cBy
scid-/scid-, and nonobese diabetic (NOD)/LtSz scid-/scid- mice
were purchased from TheJackson Laboratory (Bar Harbor, ME),
and the breeding colony was maintained under specific patho-
gen-free conditions . Plasmid constructs containing the hIL-3,
hGM-CSF, and hSCF cDNA under the control of the adenovi-
rus major late promoter (AMLP) (see Fig . 1) were kindly pro-
vided by Steven Clark (Genetics Institute, Inc ., Cambridge, MA) .
The constructs were isolated from vector sequences and coin-
jected into the male pronucleus of fertilized mouse eggs by stan-
dard techniques (22) . Transgenic foundermice were identified by
DNA Southern blot andPCR amplification ofthe human cyto-
kine genes from tail DNA . To generate inamunodeficient trans-
genic mice, transgenic founders were crossed with homozygous
SCID mice, and the progeny carrying the transgenes were back-
crossed with homozygous SCID mice up to five times .
Detection ofthe Transgenes .
￿
Transgenes were amplified using an
oligonucleotide primer for the AMLP (A : 5'-CAGGGTGTGAAG-
ACACATGTC-3') and one for each cytokine construct (GM-CSF :
5'-TCATCTGGCCGGTCTCACTC-3' ; IL-3 : 5'-GTCTGC-
TGAGCCTGAGCATTC-3' ; SCF : 5'-GTGACACTGACTCTG-
GAATC-3') . PCR was performed using conditions recommended
by the manufacturer (Perkin-Elmer Cetus Instruments, Norwalk,
CT), including [32P]dCTP for 35 cycles with each cycle at 94°C
for 1 .5 min, 58°C for 2.5 min, and 72°C for 3 min (DNA Ther-
mal Cycler model 480 ; Perkin-Elmer Cetus Instruments) . As an
'Abbreviations used in this paper : AMLP, adenovirus major late promoter;
BFU-E, burst-forming unit erythroid ; CFU-GEM, CFU granulocyte/
erythroid/macrophage/megakaryocyte ; hGM-CSF, hIL-3, hSCF, human
GM-CSF, IL-3, and stem cell factor, respectively; mRNA, messenger
RNA; NOD, nonobese diabetic ; RT, reverse transcriptase .
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internal control, a 401-bp sequence specific for the murine hemo-
globin [3 gene was amplified as described (23) . Southern blotting of
geneticDNA digested with BamHI or HindIII was performed as
described (24) .
Expression of transgene messenger RNA (mRNA) was dem-
onstrated by reverse transcriptase (RT)-PCR . Total cellular RNA
was prepared from peripheral blood, bone marrow, liver, spleen,
thymus, kidney, testes, and brain by extraction with guanidinium
isothiocyanate and treatment with DNase I . RNA was reverse
transcribed usingrandom oligonucleotide primers to cDNA, which
was then amplifed according to the conditions recommended (Per-
kin-Elmer Cetus Instruments) . Posttranscriptional splicing of an
immunoglobulin gene between the promoter and the cytokine
sequences resulted in distinct PCR bands from DNA and RNA.
Northern blot was performed as described (24) using [32P]dNTP-
labeled probes specific for the human cytokine constructs .
Preparation ofHuman Cellsfor Transplantation .
￿
Bone
￿
marrow :
Hematopoietic progenitors and stem cells expressing the human
CD34 antigen were immunoselected from healthy volunteers and
patients undergoing autologous transplantation for multiple my-
eloma using an immunoabsorption column (CEPRATE LC 34 ;
CelIPro, Inc., Bothell, WA) as described by the manufacturer .
CD34 antigen-positive cells were enriched to 80-95% purity as
confirmed by flow cytometry . Cells were washed in PBS, resus-
pended in PBS containing 10% FCS (Life Technologies, Inc .,
Gaithersburg, MD) and injected. Cord blood : Umbilical cord
blood was obtained from Indiana University Medical Center (In-
dianapolis, IN) and sent overnight after density cut separation on
Ficoll-Hypaque (<1 .077 g/cm 3 ; Pharmacia Inc., Piscataway, NJ)
to the National Institutes of Health (Bethesda, MD) on wet ice .
Upon arrival, cord blood cells were washed in PBS, resuspended
in PBS containing 10% autologous human plasma, and injected .
Transplantation Protocol .
￿
Transgenic and nontransgenic SCID
mice at 4-8 wk of age were sublethally irradiated (350 rad), and
0.2-1 X 101, human CD34 antigen-positive bone marrow cells
were intravenously injected. Alternatively, 0.5 X 10' human low-
density umbilical cord blood cells were injected . Peripheral blood
DNA was prepared for PCR at 2-wk intervals . At 8 wk after
transplantation, genomicDNA was extractedfrom bone marrow,
liver, spleen, and thymus ofselected recipients, and bone marrow
cells were cultured . In NOD-SCID mice, peripheral blood was
tested for human cells by PCR and flow cytometry 5 and 6 wk
after transplantation .
Detection ofHuman Cells in Chimeric Mice .
￿
PCR was performed
using primers specific for human a-satellite sequences on human
chromosome 17 as described (25) . Internal controls were used as
described above . The protocol was able to detect <0.01%human
DNA in a murine DNA background, and the amplification of
standardized mixtures of human and mouse DNA (100, 10, 1,
and 0.1% human DNA) was linear . For flow cytometry, periph-
eral blood-nucleated cells were washed and incubated in PBS
containing 10% ratserum and 10% FCS (Life Technologies, Inc.) .
Cells were stained with FITC-labeled Abs (1 pLg/10s cells ; Bec-
ton Dickinson & Co ., Mountain View, CA) specific for human
CD45 (panleukocytes) and PE-labeled antibodies specific for hu-
man CD14 (monocytes, neutrophils, eosinophils) or their corre-
sponding isotype antibodies (IgGl-FITC and IgG2-PE) . Cellswere
washed twice and analyzed by flow cytometry (Elite flow cyto-
meter; Coulter Corp ., Hialeah, FL) .
Clonogenic Hematopoietic Progenitor Assays .
￿
2 X 10s bone mar-
row cells were assayed for colonies derived from burst-forming
unit erythroid (BFU-E), CFU-GM, or CFU granulocyte/eryth-
roid/macrophage/megakaryocyte (CFU-GEM) in methylceltu-
Transgenic SCID Mice as aModel for Human HematopoiesisResults
AMLP
AMLP
lose medium selectively supporting growth ofhuman cells as de-
scribed (21, 26) . Human colonies were counted after 10 and 20 d
and were evaluated for human DNA by PCR .
Transgenic Mice .
￿
Transgenic mice carrying the genes for
the human cytokines IL-3, GM-CSF, and SCF were iden-
tified by PCR amplification of tail DNA using primers spe-
cific for both the AMLP and the cytokine sequences (Fig .
1) . One founder strain was selected for further study . The
presence of the transgenes was confirmed by Southern blot
using construct-specific probes (Fig . 2 A) . By comparison
of the intensities of the hybridization signals to that ofHeLa
cell DNA, we concluded that the number of each individ-
ual transgene was approximately three to five copies per
genome . The analysis of> 100 animals from five back-cross
generations revealed that all three transgenes were passed to
-50% of the animals ofboth sexes in the next generation,
indicating that all three cytokine genes had integrated at the
same site on an autosomal chromosome . RT-PCR revealed
expression of all three transgene mRNAs in all tissues
tested, including bone marrow, thymus, liver, spleen, kid-
ney, brain, and testes (Fig. 3 and data not shown) . Differen-
tial splicing of the region upstream of the cytokine cDNA
generated products that were shorter than the genomic
DNA fragment. No corresponding signal was observed in
RNA samples from nontransgenic animals or from samples
that were not treated with RT before amplification .
Northern blot analysis ofRNA from bone marrow con-
firmed expression of the human transgenes as shown in Fig .
2 B for hSCF . Transgenic mice appeared normal in pheno-
type, and no abnormalities were detected in peripheral
blood differential counts or at autopsy in comparison with
nontransgenic littermates . After crossing and back-crossing
of transgenic BALB/cBy founders to homozygous SCID
mice, absence of mature B and T lymphocytes was con-
firmed by flow cytometry in all animals used for the trans-
plantation experiments .
Transplantation ofHuman Bone Marrow into Transgenic SCID
Mice . Transgenic SCID mice were evaluated for their
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Figure 1 .
￿
The constructs used to generate mice carry-
ing the hIL-3, hGM-CSF, and hSCF transgenes. The
AMLP with its tripartate leader (TPL) is indicated. The
leader sequence contains three splice donor (SD) sites,
and an Ig intron (Ign is also shown . The approximate lo-
cation of the primers used to amplify transgene cDNAs
are indicated by arrows. The relative sizes of the possible
mRNAs from the hIL-3 transgene are shown below the
construct . The 3' ends of the constructs include se-
quences from the 3' end of the dihydrofolate reductase
(DHFR) gene and an SV40 poly A signal (SV40 poly A) .
ability to support growth and differentiation ofhuman he-
matopoietic cells . Populations ofhuman bone marrow cells
highly enriched for the presence of the human CD34 anti-
gen were simultaneously transplanted into transgenic and
nontransgenic littermates . Peripheral blood was collected
every 2 wk and analyzed for the presence ofhumanDNA
by PCR using primers specific for human ot-satellite DNA
sequences on chromosome 17 . During the first 6 wk after
transplantation, human sequences could not be detected in
either group . Subsequently, human DNA sequences were
consistently amplified in 50% oftransgenic animals between
6 and 24 wk (Table 1 and Fig . 4 D) . Comparison of the
signals from these mice with control samples diluted in
mouse DNA allowed a semiquantitative estimate of the
humanDNA . HumanDNA accounted for 0.5-1.5% of the
total DNA extracted from peripheral blood . In contrast to
transgenic recipients, only 1 of 12 nontransgenic SCID lit-
termates was positive for human cells, which accounted for
0.1% of total cells and persisted for <10 wk (Table 1 and
Fig. 4 B) . Internal control signals could be amplified from
all samples (data not shown) .
Figure 2 .
￿
Characterization ofmice carrying the hIL-3, hGM-CSF, and
hSCF transgenes . (A) Southern blot analysis ofDNA from transgenic mice
(lanes 2, 4, and 6) and nontransgenic littermates (lanes 1, 3, and 5) . The
filters were hybridized with the probes indicated above the lanes . (B) North-
ern blot analysis ofRNA extracted from the bone marrrow oftransgenec
mice (lane 8) and nontransgenic littermates (lane 7) . The filter was hy-
bridized with a probe for the hSCF mRNA (indicated above the lanes) .
Unsplice RNAd DNA
SD4
SD3 so
Sol
TPL Igl hu GM-CSF DHFR Sv ao
polyA
11
TPL Igl hu SCF EMC-LFigure 3.
￿
Splicing of transgenic mRNAs . DNA PCR was used to
demonstrate the size of the unspliced mRNA indicated above the lane
(lanes 1-3) . RT-PCR was used to evaluate mRNAs derived from the
transgenes . No messages were detected in RNA from the bone marrow
ofnontransgenic littermates (lanes 4-6) or in any from any other tissue, or
in samples not treated with RT (data not shown) . The mRNAs corre-
sponding to expression of the hSCF and hIL-3 transgenes in the bone
marrow (BAS are shown in lanes 7 and 8, respectively . The splice donor
corresponding to each message is indicated (see Fig. 1) . Similar splicing
generates several forms of the mRNA corresponding to the expression of
the hGM-CSF transgene in BM, liver (LII/), spleen (SPL), thymus (THIJ,
and heart (HE) . The splice donor corresponding to each message is indi-
cated (see Fig. 1) .
Transplantation of Human Umbilical Cord Blood Cells into
Transgenic SCID Mice . Because human umbilical cord blood
cells have been shown to engraft readily into both human
recipients (27) and SCID mice (21, 28), the engraftment of
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Figure 4 .
￿
PCR detection ofhuman a-satellite sequences in DNA ex-
tracted from the peripheral blood ofSCID mice transplanted with human
hematopoietic cells . (A) A dilution curve of human DNA diluted in in-
creasing amounts ofmouse DNA used to estimate the percentage of hu-
man cells. (B) Three representative samples from nontransgenic SCID
mice transplanted with humanbone marrow cells. Only a faint band (lane
2) is detected . (C) Three representative samples from nontransgenic SCID
mice transplanted with human cord blood cells . Only a faint band (lane 3)
is detected. (D) Three representative samples from transgenic SCID mice
transplanted with human bone marrow cells . Signals are detected in lanes
1 and 2 . (E) Three representative samples from transgenic SCID mice
transplanted with human cord blood cells . Signals are detected in lanes 1
and 3 .
human cord blood cells into transgenic SCID mice was
compared with that of adult bone marrow . Populations of
low-density cord blood cells were simultaneously injected
into transgenic SCID mice and nontransgenic littermates .
Analysis ofperipheral bloodDNA demonstrated the pres-
ence ofhuman (x-satellite sequences in 10 of 20 transgenic
animals as early as 1 wk after transplant, whereas 6wk were
required for detection using adult CD34+ bone marrow
cells . Human DNA was detected for a minimum of 13 wk
and accounted for an average of2% of totalDNA (Table 1
and Fig . 4 E), with occasional animals achieving levels %10%
human cells .A trace amount ofhuman DNA was detected
in 1 of 3 nontransgenic recipients transplanted simulta-
neously (Table 1 and Fig . 4 C) . 10 animals were killed 8
wk after transplantation . In 6 of 10 mice, humanDNA was
detected in the bone marrow, liver, and spleen, and ac-
counted for 1-2% of the total DNA ofextractedbone mar-
row and 0.1-2% in other tissues. Human hematopoietic
progenitor cells in the bone marrow of transgenic mice in-
Table 1.
￿
Detection ofHuman Cells in Peripheral Blood and Bone Marrow after Transplantation ofHuman Bone Marrow
and Umbilical Cord Blood Cells
Detection ofhuman cells in recipient mice (positive/transplanted)
Peripheral blood Bone marrow
Recipient Human cells
strain transplanted 0-6 wk 8-24 wk >8 wk
% human
BALE/c SCID CD34+BM 0/12 (ND) 1/12(0.05) 0/12 (ND)
Transgenic
BALB/c SCID CD34+BM 0/8 (ND) 4/8 (1 .0-1 .5) 4/6(l.0)
BALB/c SCID Cord blood 1/3 (0.1) 1/3(0.1) 0/3 (ND)
Transgenic
BALB/c SCID Cord blood 10/20 (1 .0-10.0) 10/20 (1.0-10.0) 5/10 (1 .0-5.0)
BM,bone marrow._S
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￿
Expression of human CD14 and CD45 antigens on periph-
eral blood cells collected from NOD-SCID mice transplanted with hu-
man cord blood cells. The results from two transplanted mice are shown
in the top half o£the figure. The negative control (untransplanted mouse
peripheral blood) and positive control (human peripheral blood) are
shown in the bottom half o£the figure.
jected with cord blood cells were grown in methylcellulose
medium designed to support the growth ofhuman BFU-E,
CFU-GM, and CFU-GEM. All three colony types were
observed in cultures 10-20 d after plating. The human ori-
gin of these colonies was verified by PCR amplification of
human ot-satellite sequences as in Fig. 4. The number of
colonies was between 1 and 10% of the colony number
that was obtained afterplating an equivalent number ofhu-
man bone marrow cells not passaged in mice.
Engraftment of Cord Blood Cells into NOD-SCID Mice.
Engraftment of human bone marrow and spleen cells into
NOD-SCID mice has been shown to be superior to other
strains of SCID mice (29, 30) . NOD-SCID mice contain
very low rejection activity due to a deficiency in B cells, T
cells, killer cells, and circulating complement (31-33). We
tested the suitability of NOD-SCID mice for short-term
engraftment using our cord blood protocol. Human cells
were observed in peripheral blood in all of 11 NOD-SCID
mice 6 wk after transplantation. PCR and flow cytometry
ofperipheral blood revealed an average of 30% human cells
(range 5-95%) among total peripheral blood cells using
monoclonal anti-human CD14 and anti-human CD45 an-
tibodies, which specifically mark human monocytes and all
leukocytes (Fig. 5) .
In this study we described a transgenic SCID mouse car-
rying hIL-3, hGM-CSF, and hSCF transgenes and com-
pared it with other SCID models for the engraftment of
human hematopoietic cells. We evaluated the effects of cy-
tokine transgene expression in two different sources of hu-
man hematopoietic cells. In previous studies using exoge-
nous cytokine support, human cells have survived for 8-10
wk and on rare occasions as long as 14 wk (17, 21) . In
SCID-hu mice, primitive fetal liver cells can differentiate
into multiple lineages, including T cells (14, 17, 34), and
can be successfully transferred to secondary recipients (35),
a hallmark ofhematopoietic stem cells (6). In our study, trans-
genic mice expressing the hIL-3, hGM-CSF, and hSCF genes
supported long-term engraftment of human bone marrow
and cord blood cells and supported human hematopoiesis
routinely for a minimum of 13 wk, and in some animals for
up to 24 wk, after transplantation. The presence ofhuman
cells over this period strongly suggests engraftment of very
primitive hematopoietic progenitors (36). Although we have
not demonstrated engraftment ofpluripotent hematopoietic
stem cells by detection of multiple hematopoietic lineages
in secondary recipients, recovery of multipotent CFU-GEM
colonies from bone marrow of transplanted mice provides
evidence for pnmtive progenitor cell engraftment. We con-
clude that engraftment of human hematopoietic cells into
SCID mice is facilitated and substantially extended by ex-
pression ofthe IL-3, GM-CSF, and SCF transgenes relative
to nontransgenic SCID mice.
Both the source of hematopoietic cells and the strain of
immunodeficient mouse have been shown to affect the en-
graftment of human cells into immunodeficient mice. Little
engraftment of human hematopoietic cells into C57BL/6-
SCID mice has been observed. Previous studies have used
either C .B-17-SCID or BALB/cBy-SCID mice, in which
repeatable but modest levels ofengraftment ofhuman bone
marrow cells is seen when exogenous cytokines are sup-
plied (16, 17). In this study we compared the engraftment
of human cord blood and bone marrow into our transgenic
BALB/cBy-SCID mice. We observed at least twofold higher
levels of engraftment ofhuman cord blood compared with
bone marrow. Engraftment of cord blood cells may be en-
hanced by mature hematopoietic cells present in the injected
low density fraction as opposed to the isolated CD34+ bone
marrow cells used for transplantation. Engraftment of cord
blood cells into C.B-17-SCID mice has been reported to
be cytokine independent (21), but our results indicate that
while cord blood cells may not require cytokine supple-
mentation to achieve short-term engraftment, more dura-
ble engraftment is seen in the transgenic BALB/cBy-SCID
mice. We infer that while the initial engraftment may be
cytokine independent, cytokine support can extend the pe-
riod of engraftment by up to 10 wk. Other possible expla-
nations for better engraftment of cord blood as opposed to
bone marrow cells might be that cord blood is more en-
riched for primitive progenitors (37), that cord blood cells
have an enhanced proliferative capacity based on their abil-
ity to generate expanded pools of progenitor cells in vitro
(38, 39), and the efficient transduction ofhuman cord blood
progenitor cells with retroviral vectors (40, 41) . Superior
engraftment ofhuman bone marrow cells has been reported
in the NK cell-deficient NOD-SCID mouse as opposed to
conventional C.B-17-SCID mice. In this study we show
that cord blood cells engraft better in NOD-SCID micethan in BALB/cBy-SCID mice . We feel that the high pro-
liferative potential of cord blood cells may account for the
cytokine-independent short-term engraftment we observed in
NOD-SCID recipients . Currently, we are evaluating whether
the expression of the human cytokine transgenes on a mu-
rine NOD-SCID genetic background will extend the high
level ofengraftment ofhuman cord blood cellsbeyond 10wk.
Contrary to reports using exogenous cytokine support
(17, 21), we were able to detect human cells in peripheral
blood of transplanted SCID mice . The only other study re-
porting human cells in peripheral blood was by Nolta et al .
(42), who used immunodeficient bnx mice transplanted with
human bone marrow and human stromal cells expressing
hIL-3 . The effects oflocal and continuous production ofhu-
man cytokines from either transgenes or transplanted stroma
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